243 related articles for article (PubMed ID: 20938174)
1. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India.
Bhengraj AR; Vardhan H; Srivastava P; Salhan S; Mittal A
Chemotherapy; 2010; 56(5):371-7. PubMed ID: 20938174
[TBL] [Abstract][Full Text] [Related]
2. Lack of mutation in macrolide resistance genes in Chlamydia trachomatis clinical isolates with decreased susceptibility to azithromycin.
Bhengraj AR; Srivastava P; Mittal A
Int J Antimicrob Agents; 2011 Aug; 38(2):178-9. PubMed ID: 21570258
[No Abstract] [Full Text] [Related]
3. Differing effects of azithromycin and doxycycline on cytokines in cells from Chlamydia trachomatis-infected women.
Srivastava P; Bhengraj AR; Jha HC; Vardhan H; Jha R; Singh LC; Salhan S; Mittal A
DNA Cell Biol; 2012 Mar; 31(3):392-401. PubMed ID: 21848430
[TBL] [Abstract][Full Text] [Related]
4. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure.
Zheng H; Xue Y; Bai S; Qin X; Lu P; Yang B
Sex Transm Dis; 2015 Mar; 42(3):115-9. PubMed ID: 25668641
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of fluoroquinolones, azithromycin and doxycycline against chlamydia trachomatis cultured from men with chronic lower urinary tract symptoms.
Smelov V; Perekalina T; Gorelov A; Smelova N; Artemenko N; Norman L
Eur Urol; 2004 Nov; 46(5):647-50. PubMed ID: 15474277
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic antimicrobial susceptibility testing of Chlamydia trachomatis isolates from patients with persistent or successfully treated infections.
Pitt R; Alexander S; Ison C; Horner P; Hathorn E; Goold P; Woodford N; Cole MJ
J Antimicrob Chemother; 2018 Mar; 73(3):680-686. PubMed ID: 29207004
[TBL] [Abstract][Full Text] [Related]
7. [Detection and the antibiotic susceptibility analysis of mycoplasma and chlamydia in urogenital tract infections of 327 cases patients with tubal infertility].
Zhou Y; Xu XL; Wang CP; Zhou M; Zeng XH
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):201-4. PubMed ID: 21977592
[TBL] [Abstract][Full Text] [Related]
8. Which treatment for genital tract Chlamydia trachomatis infection?
Tobin JM; Harindra V; Mani R
Int J STD AIDS; 2004 Nov; 15(11):737-9. PubMed ID: 15537459
[TBL] [Abstract][Full Text] [Related]
9. Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin.
Wyrick PB; Knight ST
J Antimicrob Chemother; 2004 Jul; 54(1):79-85. PubMed ID: 15163653
[TBL] [Abstract][Full Text] [Related]
10. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure.
Somani J; Bhullar VB; Workowski KA; Farshy CE; Black CM
J Infect Dis; 2000 Apr; 181(4):1421-7. PubMed ID: 10762573
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate.
Ljubin-Sternak S; Mestrovic T; Vilibic-Cavlek T; Mlinaric-Galinovic G; Sviben M; Markotic A; Skerk V
Folia Microbiol (Praha); 2013 Sep; 58(5):361-5. PubMed ID: 23271498
[TBL] [Abstract][Full Text] [Related]
12. High treatment failure rate is better explained by resistance gene detection than by minimum inhibitory concentration in patients with urogenital Chlamydia trachomatis infection.
Shao L; You C; Cao J; Jiang Y; Liu Y; Liu Q
Int J Infect Dis; 2020 Jul; 96():121-127. PubMed ID: 32173573
[TBL] [Abstract][Full Text] [Related]
13. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping.
Dean D; Suchland RJ; Stamm WE
J Infect Dis; 2000 Sep; 182(3):909-16. PubMed ID: 10950788
[TBL] [Abstract][Full Text] [Related]
14. Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy.
Horner PJ
Sex Transm Infect; 2012 Apr; 88(3):154-6. PubMed ID: 22416272
[No Abstract] [Full Text] [Related]
15. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.
Samra Z; Rosenberg S; Soffer Y; Dan M
Diagn Microbiol Infect Dis; 2001 Mar; 39(3):177-9. PubMed ID: 11337185
[TBL] [Abstract][Full Text] [Related]
16. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
[TBL] [Abstract][Full Text] [Related]
17. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis.
Skerk V; Krhen I; Lisić M; Begovac J; Roglić S; Skerk V; Sternak SL; Banaszak A; Strugar-Suica J; Vuković J
Int J Antimicrob Agents; 2004 Aug; 24(2):188-91. PubMed ID: 15288321
[TBL] [Abstract][Full Text] [Related]
18. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection.
Renault CA; Israelski DM; Levy V; Fujikawa BK; Kellogg TA; Klausner JD
Sex Health; 2011 Mar; 8(1):69-73. PubMed ID: 21371385
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of azithromycin in the treatment of female genital Chlamydia trachomatis infections].
Narcio Reyes LE; Casanova Roman G; Arredondo Garcia JL
Ginecol Obstet Mex; 1993 Sep; 61():261-4. PubMed ID: 8406112
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report.
Wang SA; Papp JR; Stamm WE; Peeling RW; Martin DH; Holmes KK
J Infect Dis; 2005 Mar; 191(6):917-23. PubMed ID: 15717267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
